Print out a brochure
for your patients with
Parkinson's disease*
Click here
Learn about drug
interaction considerations
with MIRAPEX
Click here
*  You will need Adobe® Reader®  to download
this file. If you don't have
Adobe Reader, click here
for a free and secure
download.

FOR THE INITIAL AND LONG-TERM TREATMENT OF PARKINSON'S DISEASE (PD)

In early Parkinson's disease, MIRAPEX significantly improves everyday activities and motor scores

Initial monotherapy with MIRAPEX offers effective control of early Parkinson's disease1,14

  • When used as initial monotherapy, MIRAPEX provides significant improvements in UPDRS ADL* scores, demonstrating enhanced patient functioning in as few as 3 weeks4  Learn more
  • Initiating monotherapy with MIRAPEX reduces the risk of major motor complications1†  Learn more
  • Initiating therapy with MIRAPEX helps facilitate a levodopa-saving strategy to reduce the risk of motor complications1 Learn more
Learn how MIRAPEX improves functioning when used as combination therapy

*UPDRS=Unified Parkinson's Disease Rating Scale; ADL=activities of daily living.
† Major motor complications=wearing off, dyskinesia or "on-off " functions.

 
 

Important Information about MIRAPEX: MIRAPEX is indicated for the treatment of the signs and symptoms of idiopathic Parkinson’s disease (PD).

Patients have reported falling asleep without perceived warning signs during activities of daily living, including operation of a motor vehicle, which sometimes resulted in accidents. Hallucinations and postural (orthostatic) hypotension may occur. In clinical trials for early PD, the most commonly reported side effects of MIRAPEX that were more frequent than with placebo are nausea (28% vs. 18%), dizziness (25% vs. 24%), somnolence (22% vs. 9%), insomnia (17% vs. 12%), asthenia (14% vs. 12%), and constipation (14% vs. 6%). In clinical trials for advanced PD, the most commonly reported side effects of MIRAPEX that were more frequent than with placebo are postural hypotension (53% vs. 48%), dyskinesia (47% vs. 31%), extrapyramidal syndrome (28% vs. 26%), insomnia (27% vs. 22%), dizziness (26% vs. 25%), accidental injury (17% vs. 15%), hallucinations (17% vs. 4%), and dream abnormalities (11% vs. 10%).

Patients and caregivers should be informed that impulse control disorders and compulsive behaviors have been reported in patients taking dopamine agonists, including MIRAPEX.

Please see full Prescribing Information.

This information is intended for U.S. residents only.